Brain Metastasis Velocity (BMV) Model
Why Use
Stratifying patients into high and low BMV categories can allow providers to better counsel patients on their risks of requiring additional treatments in the future, such additional SRS or whole brain radiation therapy.
When to Use
Use for patients with any primary cancer who have developed a distant brain failure (new brain metastasis) after upfront stereotactic radiosurgery (SRS). Not appropriate for use in patients who have had prior whole brain radiation therapy.
Formula
Pearls / Pitfalls
Developed to predict outcomes at the time of salvage treatment after upfront SRS. Correlates with overall survival, neurologic death, and time to additional salvage treatments by placing patients into low, intermediate, and high risk groups. Primary cancers with the largest representation in the study were breast, lung, RCC, and melanoma.
Management
For patients with low BMV (scores <4), localized therapy (e.g. SRS) might be most appropriate. Counseling patients with high BMV (scores >13) that there is an increased risk of needing additional therapies in the future, should a localized approach be considered, is an important part of management.
More Information
Interpretation: BMV Risk group Median overall survival <4 Low 12.4 months 4-13 Intermediate 8.2 months >13 High 4.3 months From Farris et al (2017) .